The agency announced its appeal of a court ruling it lost to Clover Health, which resulted in the agency recalculating the grades it gave to the payer’s Medicare Part C plans. Other insurers are now asking for the same redo, spurring CMS to appeal the initial ruling.

Users of the popular online betting marketplace can now wager on specific FDA regulatory scenarios, including when Eli Lilly’s new weight loss drug will be approved, or when camizestrant will be given the greenlight to treat breast cancer.

In theory, GLP-1 receptor agonist drugs like semaglutide and tirzepatide should save a lot of money for the health insurers that pay for them. As it turns out, the lived reality is not keeping pace with the idealistic expectation. 

The medical error is said to have occurred at Oregon Health & Science University, but wasn’t discovered until the teenager was flown to Seattle Children’s Hospital for a transplant.

1.) Some clinical AI has a fuzzy ROI. That doesn’t mean it shouldn’t be reimbursed. 2.) What makes biomedical research different from other sectors where AI has been quickly adopted? 3.) Unmoved by enthusiasm, health execs are making AI decisions around organizational priorities. 

That equates to $16.25 per share, a 6% premium over the current market price. The deal will expand Tempus’ molecular residual disease test offerings, allowing the company to better support cancer patients.

In emergency settings, female physicians order more tests and admit more patients than their male peers. The difference is not pronounced, but its presence suggests women physicians may have a greater tendency to consider peripheral assessment factors. 

Luigi Mangione, the man accused of shooting UnitedHealthcare CEO Brian Thompson, faces a second-degree murder charge in New York, which carries the possibility of life in prison. Federal prosecutors will get a second crack at him in January.

The portion of nurses regularly using AI is skyrocketing. It’s at 44% now after slouching in at just 15% a year ago. Yet only 8% of nurses say their organization has spelled out what it wants them to do with the technology.

The new-look ELANA device from AMT Medical could simplify CABG procedures and help improve patient access to minimally invasive and robotic surgical techniques.

Scaling the solution across the U.S. has the potential to mitigate the current shortfall of breast radiologists, researchers contend.